230家上市公司净利增长！A股医药生物上市公司成绩单来了

MoFo Shanghai Managing Partner Chuan Sun has been quoted in a recent article discussing the profit growth of Chinese A-share listed pharmaceutical and biological companies in 2024 and potential challenges they face.

According to Chuan, innovative pharmaceutical companies aiming to expand their business overseas need to adopt a more strategic and flexible approach.

“As a strategic priority, innovative pharmaceutical companies should begin by screening their research and development focus. This includes deciding whether to pursue PD-1, ADC, CAR-T, or other specialized areas,” said Chuan. “Next, they need to determine the mode of cooperation. For instance, if the goal is to access the global market, innovative pharmaceutical companies can tailor their approach based on their unique circumstances, selecting models such as NewCo or License-out. Finally, they should also consider asset positioning, talent acquisition, and other complementary factors to succeed in the global market.”

Chuan further emphasized the importance of flexibility in navigating the rapidly evolving pharmaceutical and biological market. He noted that innovative pharmaceutical companies should stay attuned to changes in policies, financing environments, and industry dynamics upstream and downstream, adjusting their strategies accordingly to meet diverse challenges.

Read the full article.